Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-07

Study Completion Date

2019-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical Cannabidiol Application and Skin Vascular Reactivity

NCT05456113

Effect of Drug

WITHDRAWN NA

Commercially Available Cannabis Products for Immune Support

NCT05944705

Influenza COVID-19 Common Cold

RECRUITING

Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting

NCT05003882

Pain Sleep Disturbance Anxiety

COMPLETED

Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

NCT01049373

Low Back Pain

COMPLETED PHASE3

Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Vascular Function

NCT02007304

Healthy

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Musculoskeletal Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pure Green Tablet

A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).

Group Type EXPERIMENTAL

Cannabidiol (CBD)

Intervention Type DRUG

A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabidiol (CBD)

A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female at least 21 years of age;
2. Subject has mild to moderate musculoskeletal pain;
3. Pain for greater than or equal to 10 days of each month for 3 months prior to study entry for which the pain requires treatment.
4. Has an Numeric Pain Rating Scale (NPRS) score of 3 or greater,
5. If female, subject is practicing an approved method of birth control throughout the study;
6. Subject is willing and able to comply with all protocol-specified requirements;
7. Subject is willing to take Pure Green tablets only and will not take any other pain medications,
8. Subject is willing to provide his/her written informed consent to participate in the study as stated in the informed consent document.
9. Subject is willing to document pain scale scores in a diary.

Exclusion Criteria

1. Subject has any condition for which the investigator does not feel the participant should be enrolled due to possible safety or compliance issues;
2. Subject has received treatment with an investigational drug or therapy within 30 days or 5 half-lives (whichever is longer) prior to Day 1.
3. Subject has a known allergy to active or inert ingredients of Pure Green tablets;
4. Subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: Cannabis (marijuana) or any cannabinoid products including Cannabidiol (CBD) or Tetrahydrocannabinol (THC); Any drug or herbal product that influences the endocannabinoid system (ECS));
5. Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
6. Have a history of recurrent seizures other than febrile seizures.
7. Have current or pending disability compensation or litigation issues that may compromise response to treatment, in the opinion of the investigator.
8. Have a diagnosis of inflammatory arthritis (that is, rheumatoid arthritis) or an autoimmune disorder (excluding inactive Hashimoto's thyroiditis).
9. Use of acupuncture, chiropractic maneuvers, transcutaneous electrical nerve stimulation (TENS), or similar procedures aimed to relieve any kind of pain.
10. Patients who are anticipated by the investigator to require use of analgesic agents including but not limited to non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen/paracetamol, and opioids, or other excluded medication for the duration of the study.
11. Are unwilling or unable to comply with the data collection method used to record their patient rated outcome data.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No